Top

Published in:

Open Access 06-01-2023 | Prostate Cancer

Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors

Authors: Isabel Heidrich, Benjamin Deitert, Stefan Werner, Klaus Pantel

Published in: Cancer and Metastasis Reviews | Issue 1/2023

Abstract

Cancer is one of the three leading causes of death worldwide. Even after successful therapy and achieving remission, the risk of relapse often remains. In this context, dormant residual cancer cells in secondary organs such as the bone marrow constitute the cellular reservoir from which late tumor recurrences arise. This dilemma leads the term of minimal residual disease, which reflects the presence of tumor cells disseminated from the primary lesion to distant organs in patients who lack any clinical or radiological signs of metastasis or residual tumor cells left behind after therapy that eventually lead to local recurrence. Disseminated tumor cells have the ability to survive in a dormant state following treatment and linger unrecognized for more than a decade before emerging as recurrent disease. They are able to breakup their dormant state and to readopt their proliferation under certain circumstances, which can finally lead to distant relapse and cancer-associated death. In recent years, extensive molecular and genetic characterization of disseminated tumor cells and blood-based biomarker has contributed significantly to our understanding of the frequency and prevalence of tumor dormancy. In this article, we describe the clinical relevance of disseminated tumor cells and highlight how latest advances in different liquid biopsy approaches can be used to detect, characterize, and monitor minimal residual disease in breast cancer, prostate cancer, and melanoma patients.

Schuurhuis, G. J., Heuser, M., Freeman, S., Bene, M. C., Buccisano, F., Cloos, J., et al. (2018). Minimal/measurable residual disease in AML: A consensus document from the European LeukemiaNet MRD Working Party. Blood, 131(12), 1275–1291. https://doi.org/10.1182/blood-2017-09-801498CrossRefPubMedPubMedCentral

Sosa, M. S., Bragado, P., & Aguirre-Ghiso, J. A. (2014). Mechanisms of disseminated cancer cell dormancy: An awakening field. Nature Reviews Cancer, 14(9), 611–622. https://doi.org/10.1038/nrc3793CrossRefPubMedPubMedCentral

Alix-Panabieres, C., & Pantel, K. (2021). Liquid biopsy: From discovery to clinical application. Cancer Discovery, 11(4), 858–873. https://doi.org/10.1158/2159-8290.CD-20-1311CrossRefPubMed

MacKie, R. M., Reid, R., & Junor, B. (2003). Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. New England Journal of Medicine, 348(6), 567–568. https://doi.org/10.1056/NEJM200302063480620CrossRefPubMed

Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., et al. (2007). Adaptive immunity maintains occult cancer in an equilibrium state. Nature, 450(7171), 903–907. https://doi.org/10.1038/nature06309CrossRefPubMed

Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002). Cancer immunoediting: From immunosurveillance to tumor escape. Nature Immunology, 3(11), 991–998. https://doi.org/10.1038/ni1102-991CrossRefPubMed

Eyles, J., Puaux, A. L., Wang, X., Toh, B., Prakash, C., Hong, M., et al. (2010). Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. The Journal of Clinical Investigation, 120(6), 2030–2039. https://doi.org/10.1172/JCI42002CrossRefPubMedPubMedCentral

Husemann, Y., Geigl, J. B., Schubert, F., Musiani, P., Meyer, M., Burghart, E., et al. (2008). Systemic spread is an early step in breast cancer. Cancer Cell, 13(1), 58–68. https://doi.org/10.1016/j.ccr.2007.12.003CrossRefPubMed

Hosseini, H., Obradovic, M. M. S., Hoffmann, M., Harper, K. L., Sosa, M. S., Werner-Klein, M., et al. (2016). Early dissemination seeds metastasis in breast cancer. Nature, 540(7634), 552–558. https://doi.org/10.1038/nature20785CrossRefPubMedPubMedCentral

10.

Hu, Z., Ding, J., Ma, Z., Sun, R., Seoane, J. A., Scott Shaffer, J., et al. (2019). Quantitative evidence for early metastatic seeding in colorectal cancer. Nature Genetics, 51(7), 1113–1122. https://doi.org/10.1038/s41588-019-0423-xCrossRefPubMedPubMedCentral

11.

De Angelis, M. L., Francescangeli, F., & Zeuner, A. (2019). Breast cancer stem cells as drivers of tumor chemoresistance, dormancy and relapse: new challenges and therapeutic opportunities. Cancers (Basel), 11(10), 1569. https://doi.org/10.3390/cancers11101569CrossRefPubMed

12.

Pantel, K., & Alix-Panabieres, C. (2010). Circulating tumour cells in cancer patients: Challenges and perspectives. Trends in Molecular Medicine, 16(9), 398–406. https://doi.org/10.1016/j.molmed.2010.07.001CrossRefPubMed

13.

Chaffer, C. L., & Weinberg, R. A. (2011). A perspective on cancer cell metastasis. Science, 331(6024), 1559–1564. https://doi.org/10.1126/science.1203543CrossRefPubMed

14.

Wang, M., Zhao, J., Zhang, L., Wei, F., Lian, Y., Wu, Y., et al. (2017). Role of tumor microenvironment in tumorigenesis. Journal of Cancer, 8(5), 761–773. https://doi.org/10.7150/jca.17648CrossRefPubMedPubMedCentral

15.

Joosse, S. A., Gorges, T. M., & Pantel, K. (2015). Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med, 7(1), 1–11. https://doi.org/10.15252/emmm.201303698CrossRefPubMed

16.

Werner, S., Heidrich, I., & Pantel, K. (2022). Clinical management and biology of tumor dormancy in breast cancer. Seminars in Cancer Biology, 78, 49–62. https://doi.org/10.1016/j.semcancer.2021.02.001CrossRefPubMed

17.

Park, S. Y., & Nam, J. S. (2020). The force awakens: Metastatic dormant cancer cells. Experimental & Molecular Medicine, 52(4), 569–581. https://doi.org/10.1038/s12276-020-0423-zCrossRef

18.

Blatter, S., & Rottenberg, S. (2015). Minimal residual disease in cancer therapy–small things make all the difference. Drug Resist Updat, 21–22, 1–10. https://doi.org/10.1016/j.drup.2015.08.003CrossRefPubMed

19.

Aguirre-Ghiso, J. A. (2007). Models, mechanisms and clinical evidence for cancer dormancy. Nature Reviews Cancer, 7(11), 834–846. https://doi.org/10.1038/nrc2256CrossRefPubMedPubMedCentral

20.

Saleh, T., Tyutyunyk-Massey, L., & Gewirtz, D. A. (2019). Tumor cell escape from therapy-induced senescence as a model of disease recurrence after dormancy. Cancer Research, 79(6), 1044–1046. https://doi.org/10.1158/0008-5472.CAN-18-3437CrossRefPubMed

21.

Coppe, J. P., Desprez, P. Y., Krtolica, A., & Campisi, J. (2010). The senescence-associated secretory phenotype: The dark side of tumor suppression. Annual Review of Pathology: Mechanisms of Disease, 5, 99–118. https://doi.org/10.1146/annurev-pathol-121808-102144CrossRef

22.

Dhimolea, E., de Matos Simoes, R., Kansara, D., Al’Khafaji, A., Bouyssou, J., Weng, X., et al. (2021). An embryonic diapause-like adaptation with suppressed Myc activity enables tumor treatment persistence. Cancer Cell, 39(2), 240-256e211. https://doi.org/10.1016/j.ccell.2020.12.002CrossRefPubMedPubMedCentral

23.

Rehman, S. K., Haynes, J., Collignon, E., Brown, K. R., Wang, Y., Nixon, A. M. L., et al. (2021). Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy. Cell, 184(1), 226-242 e221. https://doi.org/10.1016/j.cell.2020.11.018CrossRefPubMed

24.

Greil, R., Hutterer, E., Hartmann, T. N., & Pleyer, L. (2017). Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation. Cell Communication and Signaling: CCS, 15(1), 5. https://doi.org/10.1186/s12964-016-0155-9CrossRefPubMedPubMedCentral

25.

Raha, D., Wilson, T. R., Peng, J., Peterson, D., Yue, P., Evangelista, M., et al. (2014). The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. Cancer Research, 74(13), 3579–3590. https://doi.org/10.1158/0008-5472.CAN-13-3456CrossRefPubMed

26.

Nobre, A. R., Entenberg, D., Wang, Y., Condeelis, J., & Aguirre-Ghiso, J. A. (2018). The different routes to metastasis via hypoxia-regulated programs. Trends in Cell Biology, 28(11), 941–956. https://doi.org/10.1016/j.tcb.2018.06.008CrossRefPubMedPubMedCentral

27.

Fluegen, G., Avivar-Valderas, A., Wang, Y., Padgen, M. R., Williams, J. K., Nobre, A. R., et al. (2017). Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments. Nature Cell Biology, 19(2), 120–132. https://doi.org/10.1038/ncb3465CrossRefPubMedPubMedCentral

28.

Yu, M., Bardia, A., Aceto, N., Bersani, F., Madden, M. W., Donaldson, M. C., et al. (2014). Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science, 345(6193), 216–220. https://doi.org/10.1126/science.1253533CrossRefPubMedPubMedCentral

29.

Cheng, Y. H., Chen, Y. C., Lin, E., Brien, R., Jung, S., Chen, Y. T., et al. (2019). Hydro-Seq enables contamination-free high-throughput single-cell RNA-sequencing for circulating tumor cells. Nature Communications, 10(1), 2163. https://doi.org/10.1038/s41467-019-10122-2CrossRefPubMedPubMedCentral

30.

Gkountela, S., Castro-Giner, F., Szczerba, B. M., Vetter, M., Landin, J., Scherrer, R., et al. (2019). Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell, 176(1–2), 98-112 e114. https://doi.org/10.1016/j.cell.2018.11.046CrossRefPubMedPubMedCentral

31.

Kwan, T. T., Bardia, A., Spring, L. M., Giobbie-Hurder, A., Kalinich, M., Dubash, T., et al. (2018). A digital RNA signature of circulating tumor cells predicting early therapeutic response in localized and metastatic breast cancer. Cancer Discovery, 8(10), 1286–1299. https://doi.org/10.1158/2159-8290.CD-18-0432CrossRefPubMedPubMedCentral

32.

Pantel, K., & Alix-Panabieres, C. (2019). Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nature Reviews. Clinical Oncology, 16(7), 409–424. https://doi.org/10.1038/s41571-019-0187-3CrossRefPubMed

33.

Keller, L., & Pantel, K. (2019). Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nature Reviews Cancer, 19(10), 553–567. https://doi.org/10.1038/s41568-019-0180-2CrossRefPubMed

34.

Braun, S., Vogl, F. D., Naume, B., Janni, W., Osborne, M. P., Coombes, R. C., et al. (2005). A pooled analysis of bone marrow micrometastasis in breast cancer. New England Journal of Medicine, 353(8), 793–802. https://doi.org/10.1056/NEJMoa050434CrossRefPubMed

35.

Soler, A., Cayrefourcq, L., Mazel, M., & Alix-Panabieres, C. (2017). EpCAM-independent enrichment and detection of viable circulating tumor cells using the EPISPOT assay. Methods in Molecular Biology, 1634, 263–276. https://doi.org/10.1007/978-1-4939-7144-2_22CrossRefPubMed

36.

Koch, C., Kuske, A., Joosse, S. A., Yigit, G., Sflomos, G., Thaler, S., et al. (2020). Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity. EMBO Mol Med, 12(9), e11908. https://doi.org/10.15252/emmm.201911908CrossRefPubMedPubMedCentral

37.

Bardelli, A., & Pantel, K. (2017). Liquid Biopsies, what we do not know (yet). Cancer Cell, 31(2), 172–179. https://doi.org/10.1016/j.ccell.2017.01.002CrossRefPubMed

38.

Thierry, A. R., El Messaoudi, S., Gahan, P. B., Anker, P., & Stroun, M. (2016). Origins, structures, and functions of circulating DNA in oncology. Cancer and Metastasis Reviews, 35(3), 347–376. https://doi.org/10.1007/s10555-016-9629-xCrossRefPubMed

39.

Elazezy, M., & Joosse, S. A. (2018). Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management. Computational and Structural Biotechnology Journal, 16, 370–378. https://doi.org/10.1016/j.csbj.2018.10.002CrossRefPubMedPubMedCentral

40.

Vendrell, J. A., Mau-Them, F. T., Beganton, B., Godreuil, S., Coopman, P., & Solassol, J. (2017). Circulating cell free tumor DNA detection as a routine tool for lung cancer patient management. International Journal of Molecular Sciences, 18(2), 264. https://doi.org/10.3390/ijms18020264CrossRefPubMedPubMedCentral

41.

Chen, M., & Zhao, H. (2019). Next-generation sequencing in liquid biopsy: Cancer screening and early detection. Human Genomics, 13(1), 34. https://doi.org/10.1186/s40246-019-0220-8CrossRefPubMedPubMedCentral

42.

Medina Diaz, I., Nocon, A., Mehnert, D. H., Fredebohm, J., Diehl, F., & Holtrup, F. (2016). Performance of streck cfDNA blood collection tubes for liquid biopsy testing. PLoS ONE, 11(11), e0166354. https://doi.org/10.1371/journal.pone.0166354CrossRefPubMedPubMedCentral

43.

Razavi, P., Li, B. T., Brown, D. N., Jung, B., Hubbell, E., Shen, R., et al. (2019). High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nature Medicine, 25(12), 1928–1937. https://doi.org/10.1038/s41591-019-0652-7CrossRefPubMedPubMedCentral

44.

Sherwood, J. L., Corcoran, C., Brown, H., Sharpe, A. D., Musilova, M., & Kohlmann, A. (2016). Optimised pre-analytical methods improve KRAS mutation detection in circulating tumour DNA (ctDNA) from patients with non-small cell lung cancer (NSCLC). PLoS ONE, 11(2), e0150197. https://doi.org/10.1371/journal.pone.0150197CrossRefPubMedPubMedCentral

45.

Wild, C. P., & W. E., Stewart BW, (Eds.). (2020). World cancer report: Cancer Research for Cancer Prevention. Lyon, France: International Agency for Research on Cancer.

46.

Howlader, N., Altekruse, S. F., Li, C. I., Chen, V. W., Clarke, C. A., Ries, L. A., et al. (2014). US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst, 106(5), https://doi.org/10.1093/jnci/dju055

47.

Richman, J., & Dowsett, M. (2019). Beyond 5 years: Enduring risk of recurrence in oestrogen receptor-positive breast cancer. Nature Reviews. Clinical Oncology, 16(5), 296–311. https://doi.org/10.1038/s41571-018-0145-5CrossRefPubMed

48.

Smith, G. L. (2014). The long and short of tamoxifen therapy: A review of the ATLAS Trial. Journal of the Advanced Practitioner in Oncology, 5(1), 57–60.PubMedPubMedCentral

49.

Early Breast Cancer Trialists’ Collaborative, G, Davies, C., Godwin, J., Gray, R., Clarke, M., Cutter, D., et al. (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, 378(9793), 771–784. https://doi.org/10.1016/S0140-6736(11)60993-8CrossRef

50.

Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., et al. (2013). Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet, 381(9869), 805–816. https://doi.org/10.1016/S0140-6736(12)61963-1CrossRefPubMedPubMedCentral

51.

Pedersen, R. N., Esen, B. O., Mellemkjaer, L., Christiansen, P., Ejlertsen, B., Lash, T. L., et al. (2022). The incidence of breast cancer recurrence 10–32 years after primary diagnosis. Journal of the National Cancer Institute, 114(3), 391–399. https://doi.org/10.1093/jnci/djab202CrossRefPubMed

52.

Pan, H., Gray, R., Braybrooke, J., Davies, C., Taylor, C., McGale, P., et al. (2017). 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. New England Journal of Medicine, 377(19), 1836–1846. https://doi.org/10.1056/NEJMoa1701830CrossRefPubMed

53.

Pedersen, R. N., Mellemkjaer, L., Ejlertsen, B., Norgaard, M., & Cronin-Fenton, D. P. (2022). Mortality after late breast cancer recurrence in Denmark. Journal of Clinical Oncology, 40(13), 1450–1463. https://doi.org/10.1200/JCO.21.02062CrossRefPubMed

54.

Gray, R. G., Rea, D., Handley, K., Bowden, S. J., Perry, P., Earl, H. M., et al. (2013). Journal of Clinical Oncology, 31(18_suppl), 5–5. https://doi.org/10.1200/jco.2013.31.18_suppl.5CrossRef

55.

Goss, P. E., Ingle, J. N., Pritchard, K. I., Robert, N. J., Muss, H., Gralow, J., et al. (2016). Extending aromatase-inhibitor adjuvant therapy to 10 years. New England Journal of Medicine, 375(3), 209–219. https://doi.org/10.1056/NEJMoa1604700CrossRefPubMed

56.

Baselga, J., Semiglazov, V., van Dam, P., Manikhas, A., Bellet, M., Mayordomo, J., et al. (2009). Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. Journal of Clinical Oncology, 27(16), 2630–2637. https://doi.org/10.1200/JCO.2008.18.8391CrossRefPubMed

57.

Fehm, T., Muller, V., Alix-Panabieres, C., & Pantel, K. (2008). Micrometastatic spread in breast cancer: Detection, molecular characterization and clinical relevance. Breast Cancer Research, 10(Suppl 1), S1. https://doi.org/10.1186/bcr1869CrossRefPubMedPubMedCentral

58.

Hartkopf, A. D., Taran, F. A., Wallwiener, M., Hahn, M., Becker, S., Solomayer, E. F., et al. (2014). Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis. European Journal of Cancer, 50(15), 2550–2559. https://doi.org/10.1016/j.ejca.2014.06.025CrossRefPubMed

59.

Hartkopf, A. D., Brucker, S. Y., Taran, F. A., Harbeck, N., von Au, A., Naume, B., et al. (2021). Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. European Journal of Cancer, 154, 128–137. https://doi.org/10.1016/j.ejca.2021.06.028CrossRefPubMed

60.

Singh, P., Tevis, S. E., Hall, C. S., Meas, S., Hwang, R. F., & Lucci, A. (2020). Correlation of circulating or disseminated tumor cells with the Oncotype DX Recurrence Score. Breast Cancer Research and Treatment, 184(3), 683–687. https://doi.org/10.1007/s10549-020-05882-1CrossRefPubMed

61.

Hartkopf, A. D., Banys, M., Meier-Stiegen, F., Hahn, M., Rohm, C., Hoffmann, J., et al. (2013). The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse. Breast Cancer Research and Treatment, 138(2), 509–517. https://doi.org/10.1007/s10549-013-2470-9CrossRefPubMed

62.

Amir, E., Ooi, W. S., Simmons, C., Kahn, H., Christakis, M., Popovic, S., et al. (2008). Discordance between receptor status in primary and metastatic breast cancer: An exploratory study of bone and bone marrow biopsies. Clinical Oncology (Royal College of Radiologists), 20(10), 763–768. https://doi.org/10.1016/j.clon.2008.08.005CrossRef

63.

Rack, B., Zombirt, E., Trapp, E., Juckstock, J., Andergassen, U., Neugebauer, J., et al. (2016). Comparison of HER2 expression in primary tumor and disseminated tumor cells in the bone marrow of breast cancer patients. Oncology, 90(4), 232–238. https://doi.org/10.1159/000442986CrossRefPubMed

64.

Rack, B., Juckstock, J., Gunthner-Biller, M., Andergassen, U., Neugebauer, J., Hepp, P., et al. (2012). Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients. Archives of Gynecology and Obstetrics, 285(2), 485–492. https://doi.org/10.1007/s00404-011-1954-2CrossRefPubMed

65.

Magbanua, M. J. M., Rugo, H. S., Hauranieh, L., Roy, R., Scott, J. H., Lee, J. C., et al. (2018). Genomic and expression profiling reveal molecular heterogeneity of disseminated tumor cells in bone marrow of early breast cancer. NPJ Breast Cancer, 4, 31. https://doi.org/10.1038/s41523-018-0083-5CrossRefPubMedPubMedCentral

66.

Balic, M., Lin, H., Young, L., Hawes, D., Giuliano, A., McNamara, G., et al. (2006). Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clinical Cancer Research, 12(19), 5615–5621. https://doi.org/10.1158/1078-0432.CCR-06-0169CrossRefPubMed

67.

Klein, C. A. (2009). Parallel progression of primary tumours and metastases. Nature Reviews Cancer, 9(4), 302–312. https://doi.org/10.1038/nrc2627CrossRefPubMed

68.

Capp, J. P., Nedelcu, A. M., Dujon, A. M., Roche, B., Catania, F., Ujvari, B., et al. (2021). Does cancer biology rely on Parrondo’s principles? Cancers (Basel), 13(9), 2197. https://doi.org/10.3390/cancers13092197CrossRefPubMed

69.

Duffy, M. J., Evoy, D., & McDermott, E. W. (2010). CA 15–3: Uses and limitation as a biomarker for breast cancer. Clinica Chimica Acta, 411(23–24), 1869–1874. https://doi.org/10.1016/j.cca.2010.08.039CrossRef

70.

Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., et al. (2007). American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of Clinical Oncology, 25(33), 5287–5312. https://doi.org/10.1200/JCO.2007.14.2364CrossRefPubMed

71.

Lauro, S., Trasatti, L., Bordin, F., Lanzetta, G., Bria, E., Gelibter, A., et al. (1999). Comparison of CEA, MCA, CA 15–3 and CA 27–29 in follow-up and monitoring therapeutic response in breast cancer patients. Anticancer Research, 19(4C), 3511–3515.PubMed

72.

Rack, B., Schindlbeck, C., Juckstock, J., Andergassen, U., Hepp, P., Zwingers, T., et al. (2014). Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst, 106(5), https://doi.org/10.1093/jnci/dju066

73.

Pierga, J. Y., Bidard, F. C., Mathiot, C., Brain, E., Delaloge, S., Giachetti, S., et al. (2008). Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clinical Cancer Research, 14(21), 7004–7010. https://doi.org/10.1158/1078-0432.CCR-08-0030CrossRefPubMed

74.

Lucci, A., Hall, C. S., Lodhi, A. K., Bhattacharyya, A., Anderson, A. E., Xiao, L., et al. (2012). Circulating tumour cells in non-metastatic breast cancer: A prospective study. The lancet Oncology, 13(7), 688–695. https://doi.org/10.1016/S1470-2045(12)70209-7CrossRefPubMed

75.

Bidard, F. C., Belin, L., Delaloge, S., Lerebours, F., Ngo, C., Reyal, F., et al. (2013). Time-dependent prognostic impact of circulating tumor cells detection in non-metastatic breast cancer: 70-month analysis of the REMAGUS02 Study. Int J Breast Cancer, 2013, 130470. https://doi.org/10.1155/2013/130470CrossRefPubMedPubMedCentral

76.

Trapp, E., Janni, W., Schindlbeck, C., Juckstock, J., Andergassen, U., de Gregorio, A., et al. (2019). Presence of circulating tumor cells in high-risk early breast cancer during follow-up and prognosis. Journal of the National Cancer Institute, 111(4), 380–387. https://doi.org/10.1093/jnci/djy152CrossRefPubMed

77.

Sparano, J., O’Neill, A., Alpaugh, K., Wolff, A. C., Northfelt, D. W., Dang, C. T., et al. (2018). Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: A secondary analysis of a randomized clinical trial. JAMA Oncology, 4(12), 1700–1706. https://doi.org/10.1001/jamaoncol.2018.2574CrossRefPubMedPubMedCentral

78.

Kim, M. Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H., Norton, L., et al. (2009). Tumor self-seeding by circulating cancer cells. Cell, 139(7), 1315–1326. https://doi.org/10.1016/j.cell.2009.11.025CrossRefPubMedPubMedCentral

79.

Diamantopoulou, Z., Castro-Giner, F., Schwab, F. D., Foerster, C., Saini, M., Budinjas, S., et al. (2022). The metastatic spread of breast cancer accelerates during sleep. Nature, 607(7917), 156–162. https://doi.org/10.1038/s41586-022-04875-yCrossRefPubMed

80.

Cortes-Hernandez, L. E., Eslami, S. Z., Dujon, A. M., Giraudeau, M., Ujvari, B., Thomas, F., et al. (2020). Do malignant cells sleep at night? Genome Biology, 21(1), 276. https://doi.org/10.1186/s13059-020-02179-wCrossRefPubMedPubMedCentral

81.

Pascual, J., Attard, G., Bidard, F. C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., et al. (2022). ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group. Annals of Oncology, 33(8), 750–768. https://doi.org/10.1016/j.annonc.2022.05.520CrossRefPubMed

82.

Coombes, R. C., Page, K., Salari, R., Hastings, R. K., Armstrong, A., Ahmed, S., et al. (2019). Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clinical Cancer Research, 25(14), 4255–4263. https://doi.org/10.1158/1078-0432.CCR-18-3663CrossRefPubMed

83.

Dawson, S. J., Tsui, D. W., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S. F., et al. (2013). Analysis of circulating tumor DNA to monitor metastatic breast cancer. New England Journal of Medicine, 368(13), 1199–1209. https://doi.org/10.1056/NEJMoa1213261CrossRefPubMed

84.

Garcia-Murillas, I., Schiavon, G., Weigelt, B., Ng, C., Hrebien, S., Cutts, R. J., et al. (2015). Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Science Translational Medicine, 7(302), 302ra133. https://doi.org/10.1126/scitranslmed.aab0021CrossRefPubMed

85.

Rawla, P. (2019). Epidemiology of prostate cancer. World Journal of Oncology, 10(2), 63–89.CrossRefPubMedPubMedCentral

86.

Pound, C. R., Partin, A. W., Eisenberger, M. A., Chan, D. W., Pearson, J. D., & Walsh, P. C. (1999). Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 281(17), 1591–1597. https://doi.org/10.1001/jama.281.17.1591CrossRefPubMed

87.

Risbridger, G. P., Davis, I. D., Birrell, S. N., & Tilley, W. D. (2010). Breast and prostate cancer: More similar than different. Nature Reviews Cancer, 10(3), 205–212. https://doi.org/10.1038/nrc2795CrossRefPubMed

88.

Schroder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L., Zappa, M., Nelen, V., et al. (2014). Screening and prostate cancer mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet, 384(9959), 2027–2035. https://doi.org/10.1016/S0140-6736(14)60525-0CrossRefPubMedPubMedCentral

89.

Bubendorf, L., Schopfer, A., Wagner, U., Sauter, G., Moch, H., Willi, N., et al. (2000). Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Human Pathology, 31(5), 578–583. https://doi.org/10.1053/hp.2000.6698CrossRefPubMed

90.

Rueda, O. M., Sammut, S. J., Seoane, J. A., Chin, S. F., Caswell-Jin, J. L., Callari, M., et al. (2019). Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups. Nature, 567(7748), 399–404. https://doi.org/10.1038/s41586-019-1007-8CrossRefPubMedPubMedCentral

91.

Hofbauer, L. C., Bozec, A., Rauner, M., Jakob, F., Perner, S., & Pantel, K. (2021). Novel approaches to target the microenvironment of bone metastasis. Nature Reviews. Clinical Oncology, 18(8), 488–505. https://doi.org/10.1038/s41571-021-00499-9CrossRefPubMed

92.

Schlimok, G., Funke, I., Holzmann, B., Gottlinger, G., Schmidt, G., Hauser, H., et al. (1987). Micrometastatic cancer cells in bone marrow: In vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci U S A, 84(23), 8672–8676. https://doi.org/10.1073/pnas.84.23.8672CrossRefPubMedPubMedCentral

93.

Pantel, K., Aignherr, C., Kollermann, J., Caprano, J., Riethmuller, G., & Kollermann, M. W. (1995). Immunocytochemical detection of isolated tumour cells in bone marrow of patients with untreated stage C prostatic cancer. European Journal of Cancer, 31A(10), 1627–1632. https://doi.org/10.1016/0959-8049(95)00290-yCrossRefPubMed

94.

Oberneder, R., Riesenberg, R., Kriegmair, M., Bitzer, U., Klammert, R., Schneede, P., et al. (1994). Immunocytochemical detection and phenotypic characterization of micrometastatic tumour cells in bone marrow of patients with prostate cancer. Urological Research, 22(1), 3–8. https://doi.org/10.1007/BF00431541CrossRefPubMed

95.

Riesenberg, R., Oberneder, R., Kriegmair, M., Epp, M., Bitzer, U., Hofstetter, A., et al. (1993). Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cells. Histochemistry, 99(1), 61–66. https://doi.org/10.1007/BF00268022CrossRefPubMed

96.

Slovin, S. F., & Scher, H. I. (1998). Detectable tumor cells in the blood and bone marrow: Smoke or fire? Cancer, 83(3), 394–398. https://doi.org/10.1002/(sici)1097-0142(19980801)83:3%3c394::aid-cncr2%3e3.0.co;2-pCrossRefPubMed

97.

Mueller, P., Carroll, P., Bowers, E., Moore, D., 2nd., Cher, M., Presti, J., et al. (1998). Low frequency epithelial cells in bone marrow aspirates from prostate carcinoma patients are cytogenetically aberrant. Cancer, 83(3), 538–546.CrossRefPubMed

98.

Holcomb, I. N., Grove, D. I., Kinnunen, M., Friedman, C. L., Gallaher, I. S., Morgan, T. M., et al. (2008). Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Research, 68(14), 5599–5608. https://doi.org/10.1158/0008-5472.CAN-08-0812CrossRefPubMedPubMedCentral

99.

Guzvic, M., Braun, B., Ganzer, R., Burger, M., Nerlich, M., Winkler, S., et al. (2014). Combined genome and transcriptome analysis of single disseminated cancer cells from bone marrow of prostate cancer patients reveals unexpected transcriptomes. Cancer Research, 74(24), 7383–7394. https://doi.org/10.1158/0008-5472.CAN-14-0934CrossRefPubMed

100.

Chery, L., Lam, H. M., Coleman, I., Lakely, B., Coleman, R., Larson, S., et al. (2014). Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways. Oncotarget, 5(20), 9939–9951. https://doi.org/10.18632/oncotarget.2480CrossRefPubMedPubMedCentral

101.

Berg, A., Berner, A., Lilleby, W., Bruland, O. S., Fossa, S. D., Nesland, J. M., et al. (2007). Impact of disseminated tumor cells in bone marrow at diagnosis in patients with nonmetastatic prostate cancer treated by definitive radiotherapy. International Journal of Cancer, 120(8), 1603–1609. https://doi.org/10.1002/ijc.22488CrossRefPubMed

102.

Kollermann, J., Weikert, S., Schostak, M., Kempkensteffen, C., Kleinschmidt, K., Rau, T., et al. (2008). Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. Journal of Clinical Oncology, 26(30), 4928–4933. https://doi.org/10.1200/JCO.2007.15.0441CrossRefPubMed

103.

Morgan, T. M., Lange, P. H., Porter, M. P., Lin, D. W., Ellis, W. J., Gallaher, I. S., et al. (2009). Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clinical Cancer Research, 15(2), 677–683. https://doi.org/10.1158/1078-0432.CCR-08-1754CrossRefPubMedPubMedCentral

104.

Weckermann, D., Polzer, B., Ragg, T., Blana, A., Schlimok, G., Arnholdt, H., et al. (2009). Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. Journal of Clinical Oncology, 27(10), 1549–1556. https://doi.org/10.1200/JCO.2008.17.0563CrossRefPubMed

105.

Lilleby, W., Stensvold, A., Mills, I. G., & Nesland, J. M. (2013). Disseminated tumor cells and their prognostic significance in nonmetastatic prostate cancer patients. International Journal of Cancer, 133(1), 149–155. https://doi.org/10.1002/ijc.28002CrossRefPubMed

106.

Todenhofer, T., Hennenlotter, J., Faber, F., Wallwiener, D., Schilling, D., Kuhs, U., et al. (2015). Significance of apoptotic and non-apoptotic disseminated tumor cells in the bone marrow of patients with clinically localized prostate cancer. Prostate, 75(6), 637–645. https://doi.org/10.1002/pros.22947CrossRefPubMed

107.

Scher, H. I., & Pantel, K. (2009). Bone marrow aspiration for disseminated tumor cell detection: A must-have test or is the jury still out? Journal of Clinical Oncology, 27(10), 1531–1533. https://doi.org/10.1200/JCO.2008.21.2092CrossRefPubMed

108.

Chalfin, H. J., Glavaris, S. A., Malihi, P. D., Sperger, J. M., Gorin, M. A., Lu, C., et al. (2018). Prostate cancer disseminated tumor cells are rarely detected in the bone marrow of patients with localized disease undergoing radical prostatectomy across multiple rare cell detection platforms. Journal of Urology, 199(6), 1494–1501. https://doi.org/10.1016/j.juro.2018.01.033CrossRefPubMed

109.

Pantel, K., Hille, C., & Scher, H. I. (2019). Circulating tumor cells in prostate cancer: From discovery to clinical utility. Clinical Chemistry, 65(1), 87–99. https://doi.org/10.1373/clinchem.2018.287102CrossRefPubMed

110.

Danila, D. C., Heller, G., Gignac, G. A., Gonzalez-Espinoza, R., Anand, A., Tanaka, E., et al. (2007). Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clinical Cancer Research, 13(23), 7053–7058. https://doi.org/10.1158/1078-0432.CCR-07-1506CrossRefPubMed

111.

de Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., et al. (2008). Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clinical Cancer Research, 14(19), 6302–6309. https://doi.org/10.1158/1078-0432.CCR-08-0872CrossRefPubMed

112.

Riethdorf, S., Fritsche, H., Muller, V., Rau, T., Schindlbeck, C., Rack, B., et al. (2007). Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: A validation study of the Cell Search system. Clinical Cancer Research, 13(3), 920–928. https://doi.org/10.1158/1078-0432.CCR-06-1695CrossRefPubMed

113.

Knipper, S., Riethdorf, S., Werner, S., Tilki, D., Graefen, M., Pantel, K., et al. (2021). Possible role of circulating tumour cells for prediction of salvage lymph node dissection outcome in patients with early prostate cancer recurrence. Eur Urol Open Sci, 34, 55–58. https://doi.org/10.1016/j.euros.2021.09.017CrossRefPubMedPubMedCentral

114.

Chen, S., Tauber, G., Langsenlehner, T., Schmolzer, L. M., Potscher, M., Riethdorf, S., et al. (2019). In vivo detection of circulating tumor cells in high-risk non-metastatic prostate cancer patients undergoing radiotherapy. Cancers (Basel), 11(7), 933. https://doi.org/10.3390/cancers11070933CrossRefPubMed

115.

Kuske, A., Gorges, T. M., Tennstedt, P., Tiebel, A. K., Pompe, R., Preisser, F., et al. (2016). Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients. Science and Reports, 6, 39736. https://doi.org/10.1038/srep39736CrossRef

116.

Budna-Tukan, J., Swierczewska, M., Mazel, M., Cieslikowski, W. A., Ida, A., Jankowiak, A., et al. (2019). Analysis of circulating tumor cells in patients with non-metastatic high-risk prostate cancer before and after radiotherapy using three different enumeration assays. Cancers (Basel), 11(6), 802. https://doi.org/10.3390/cancers11060802CrossRefPubMed

117.

Cieslikowski, W. A., Budna-Tukan, J., Swierczewska, M., Ida, A., Hrab, M., Jankowiak, A., et al. (2020). Circulating tumor cells as a marker of disseminated disease in patients with newly diagnosed high-risk prostate cancer. Cancers (Basel), 12(1), 160. https://doi.org/10.3390/cancers12010160CrossRefPubMed

118.

van der Toom, E. E., Axelrod, H. D., de la Rosette, J. J., de Reijke, T. M., Pienta, K. J., & Valkenburg, K. C. (2019). Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies. Nature Reviews. Urology, 16(1), 7–22. https://doi.org/10.1038/s41585-018-0119-5CrossRefPubMedPubMedCentral

119.

Gorges, T. M., Kuske, A., Rock, K., Mauermann, O., Muller, V., Peine, S., et al. (2016). Accession of tumor heterogeneity by multiplex transcriptome profiling of single circulating tumor cells. Clinical Chemistry, 62(11), 1504–1515. https://doi.org/10.1373/clinchem.2016.260299CrossRefPubMed

120.

Murray, N. P., Aedo, S., Fuentealba, C., Reyes, E., Salazar, A., Lopez, M. A., et al. (2019). Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy. Ecancermedicalscience, 13, 934. https://doi.org/10.3332/ecancer.2019.934CrossRefPubMedPubMedCentral

121.

Lianidou, E. (2021). Detection and relevance of epigenetic markers on ctDNA: Recent advances and future outlook. Molecular Oncology, 15(6), 1683–1700. https://doi.org/10.1002/1878-0261.12978CrossRefPubMedPubMedCentral

122.

Haldrup, C., Pedersen, A. L., Ogaard, N., Strand, S. H., Hoyer, S., Borre, M., et al. (2018). Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies. Molecular Oncology, 12(4), 545–560. https://doi.org/10.1002/1878-0261.12183CrossRefPubMedPubMedCentral

123.

Yu, W., Hurley, J., Roberts, D., Chakrabortty, S. K., Enderle, D., Noerholm, M., et al. (2021). Exosome-based liquid biopsies in cancer: Opportunities and challenges. Annals of Oncology, 32(4), 466–477. https://doi.org/10.1016/j.annonc.2021.01.074CrossRefPubMed

124.

Moding, E. J., Nabet, B. Y., Alizadeh, A. A., & Diehn, M. (2021). Detecting liquid remnants of solid tumors: Circulating tumor DNA minimal residual disease. Cancer Discovery, 11(12), 2968–2986. https://doi.org/10.1158/2159-8290.CD-21-0634CrossRefPubMedPubMedCentral

125.

Jun, T., & Oh, W. K. (2022). Does circulating tumor DNA measure up to prostate-specific antigen? JAMA Oncology, 8(7), 972–974. https://doi.org/10.1001/jamaoncol.2022.0511CrossRefPubMed

126.

Hellmund, P., Schmitt, J., Roessler, M., Meier, F., & Schoffer, O. (2020). Targeted and checkpoint inhibitor therapy of metastatic malignant melanoma in Germany, 2000–2016. Cancers (Basel), 12(9), 2354. https://doi.org/10.3390/cancers12092354CrossRefPubMed

127.

Koch-Institut, R., & e.V., G. d. e. K. i. D. (2019). Krebs in Deutschland 2015/2016. https://doi.org/10.25646/5977

128.

Gershenwald, J. E., & Scolyer, R. A. (2018). Melanoma staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. Annals of Surgical Oncology, 25(8), 2105–2110. https://doi.org/10.1245/s10434-018-6513-7CrossRefPubMed

129.

D’Arcy, C., & Kiel, C. (2021). Cell adhesion molecules in normal skin and melanoma. Biomolecules, 11(8), 1213. https://doi.org/10.3390/biom11081213CrossRefPubMedPubMedCentral

130.

North, S., Moenner, M., & Bikfalvi, A. (2005). Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. Cancer Letters, 218(1), 1–14. https://doi.org/10.1016/j.canlet.2004.08.007CrossRefPubMed

131.

Bergers, G., & Hanahan, D. (2008). Modes of resistance to anti-angiogenic therapy. Nature Reviews Cancer, 8(8), 592–603. https://doi.org/10.1038/nrc2442CrossRefPubMedPubMedCentral

132.

Szeimies, R., Hauschild, A., Garbe, C., Kaufmann, R., & Landthaler, M. (2009). Tumoren der Haut. 1. edition. Stuttgart: Thieme. https://doi.org/10.1055/b-002-37780

133.

Eggermont, A. M. M., Blank, C. U., Mandala, M., Long, G. V., Atkinson, V. G., Dalle, S., et al. (2020). Longer Follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III Mmelanoma: Updated results from the EORTC 1325-MG/KEYNOTE-054 Trial. Journal of Clinical Oncology, 38(33), 3925–3936. https://doi.org/10.1200/JCO.20.02110CrossRefPubMedPubMedCentral

134.

Owen, C. N., Shoushtari, A. N., Chauhan, D., Palmieri, D. J., Lee, B., Rohaan, M. W., et al. (2020). Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy(). Annals of Oncology, 31(8), 1075–1082. https://doi.org/10.1016/j.annonc.2020.04.471CrossRefPubMed

135.

Grossman, D., Kim, C. C., Hartman, R. I., Berry, E., Nelson, K. C., Okwundu, N., et al. (2019). Prognostic gene expression profiling in melanoma: necessary steps to incorporate into clinical practice. Melanoma Management, 6(4), MMT32. https://doi.org/10.2217/mmt-2019-0016CrossRefPubMedPubMedCentral

136.

Yousaf, A., Tjien-Fooh, F. J., Rentroia-Pacheco, B., Quattrocchi, E., Kobic, A., Tempel, D., et al. (2021). Validation of CP-GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: a U.S. cohort study. Intenational Journal of Dermatology, 60(7), 851–856. https://doi.org/10.1111/ijd.15594CrossRef

137.

Keung, E. Z., & Gershenwald, J. E. (2018). The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Review of Anticancer Therapy, 18, 775–784. https://doi.org/10.1080/14737140.2018.1489246CrossRefPubMedPubMedCentral

138.

Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., et al. (2021). CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma. Journal of Clinical Oncology, 39(15_suppl), 9506–9506. https://doi.org/10.1200/JCO.2021.39.15_suppl.9506CrossRef

139.

Weilbaecher, K. N., Guise, T. A., & McCauley, L. K. (2011). Cancer to bone: A fatal attraction. Nature Reviews Cancer, 11(6), 411–425. https://doi.org/10.1038/nrc3055CrossRefPubMedPubMedCentral

140.

Chernysheva, O., Markina, I., Demidov, L., Kupryshina, N., Chulkova, S., Palladina, A., et al. (2019). Bone marrow involvement in melanoma. potentials for detection of disseminated tumor cells and characterization of their subsets by flow cytometry. Cells, 8(6), 627. https://doi.org/10.3390/cells8060627CrossRefPubMedPubMedCentral

141.

Flores-Guzman, F., Utikal, J., & Umansky, V. (2020). Dormant tumor cells interact with memory CD8(+) T cells in RET transgenic mouse melanoma model. Cancer Letters, 474, 74–81. https://doi.org/10.1016/j.canlet.2020.01.016CrossRefPubMed

142.

Gutzmer, R., Stroyakovskiy, D., Gogas, H., Robert, C., Lewis, K., Protsenko, S., et al. (2020). Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): Primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 395(10240), 1835–1844. https://doi.org/10.1016/S0140-6736(20)30934-XCrossRefPubMed

143.

Fumoleau, P., Chevallier, B., Kerbrat, P., Krakowski, Y., Misset, J. L., Maugard-Louboutin, C., et al. (1996). A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC. Annals of Oncology, 7(2), 165–171. https://doi.org/10.1093/oxfordjournals.annonc.a010544CrossRefPubMed

144.

Heidrich, I., Ackar, L., Mossahebi Mohammadi, P., & Pantel, K. (2021). Liquid biopsies: Potential and challenges. International Journal of Cancer, 148(3), 528–545. https://doi.org/10.1002/ijc.33217CrossRefPubMed

145.

Kuske, M., Westphal, D., Wehner, R., Schmitz, M., Beissert, S., Praetorius, C., et al. (2018). Immunomodulatory effects of BRAF and MEK inhibitors: Implications for melanoma therapy. Pharmacological Research, 136, 151–159. https://doi.org/10.1016/j.phrs.2018.08.019CrossRefPubMed

146.

Braune, J., Keller, L., Schiller, F., Graf, E., Rafei-Shamsabadi, D., Wehrle, J., et al. (2020). Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma. JCO Precision Oncology, 4, 20–31. https://doi.org/10.1200/PO.19.00174CrossRefPubMed

147.

Syeda, M. M., Wiggins, J. M., Corless, B. C., Long, G. V., Flaherty, K. T., Schadendorf, D., et al. (2021). Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: A clinical validation study. The Lancet Oncology, 22(3), 370–380. https://doi.org/10.1016/S1470-2045(20)30726-9CrossRefPubMedPubMedCentral

148.

Lee, J. H., Saw, R. P., Thompson, J. F., Lo, S., Spillane, A. J., Shannon, K. F., et al. (2019). Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. Annals of Oncology, 30(5), 815–822. https://doi.org/10.1093/annonc/mdz075CrossRefPubMedPubMedCentral

149.

Li, X., Karras, P., Torres, R., Rambow, F., van den Oord, J., Marine, J. C., et al. (2020). Disseminated melanoma cells transdifferentiate into endothelial cells in intravascular niches at metastatic sites. Cell Reports, 31(11), 107765. https://doi.org/10.1016/j.celrep.2020.107765CrossRefPubMed

150.

Gorges, K., Wiltfang, L., Gorges, T. M., Sartori, A., Hildebrandt, L., Keller, L., et al. (2019). Intra-patient heterogeneity of circulating tumor cells and circulating tumor DNA in blood of melanoma patients. Cancers (Basel), 11(11), 1685. https://doi.org/10.3390/cancers11111685CrossRefPubMed

151.

Tan, L., Sandhu, S., Lee, R. J., Li, J., Callahan, J., Ftouni, S., et al. (2019). Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA. Annals of Oncology, 30(5), 804–814. https://doi.org/10.1093/annonc/mdz048CrossRefPubMedPubMedCentral

152.

Lee, J. H., Long, G. V., Boyd, S., Lo, S., Menzies, A. M., Tembe, V., et al. (2017). Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Annals of Oncology, 28(5), 1130–1136. https://doi.org/10.1093/annonc/mdx026CrossRefPubMed

153.

Marczynski, G. T., Laus, A. C., Dos Reis, M. B., Reis, R. M., & Vazquez, V. L. (2020). Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients. Science and Reports, 10(1), 18682. https://doi.org/10.1038/s41598-020-75792-1CrossRef

154.

Weidenfeld, K., & Barkan, D. (2018). EMT and stemness in tumor dormancy and outgrowth: Are they intertwined processes? Frontiers in Oncology, 8, 381. https://doi.org/10.3389/fonc.2018.00381CrossRefPubMedPubMedCentral

155.

Felici, C., Mannavola, F., Stucci, L. S., Duda, L., Cafforio, P., Porta, C., et al. (2022). Circulating tumor cells from melanoma patients show phenotypic plasticity and metastatic potential in xenograft NO.DCB17 mice. BMC Cancer, 22(1), 754. https://doi.org/10.1186/s12885-022-09829-1CrossRefPubMedPubMedCentral

156.

Voit, C., Kron, M., Rademaker, J., Schwurzer-Voit, M., Sterry, W., Weber, L., et al. (2005). Molecular staging in stage II and III melanoma patients and its effect on long-term survival. Journal of Clinical Oncology, 23(6), 1218–1227. https://doi.org/10.1200/JCO.2005.04.098CrossRefPubMed

157.

Lucci, A., Hall, C. S., Patel, S. P., Narendran, B., Bauldry, J. B., Royal, R. E., et al. (2020). Circulating tumor cells and early relapse in node-positive melanoma. Clinical Cancer Research, 26(8), 1886–1895. https://doi.org/10.1158/1078-0432.CCR-19-2670CrossRefPubMed

158.

Koyanagi, K., O’Day, S. J., Gonzalez, R., Lewis, K., Robinson, W. A., Amatruda, T. T., et al. (2005). Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: Outcome prediction in a multicenter trial. Journal of Clinical Oncology, 23(31), 8057–8064. https://doi.org/10.1200/JCO.2005.02.0958CrossRefPubMed

159.

Kiniwa, Y., Nakamura, K., Mikoshiba, A., Ashida, A., Akiyama, Y., Morimoto, A., et al. (2021). Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation. BMC Cancer, 21(1), 287. https://doi.org/10.1186/s12885-021-08016-yCrossRefPubMedPubMedCentral

160.

Vishnoi, M., Boral, D., Liu, H., Sprouse, M. L., Yin, W., Goswami-Sewell, D., et al. (2018). Targeting USP7 identifies a metastasis-competent state within bone marrow-resident melanoma CTCs. Cancer Research, 78(18), 5349–5362. https://doi.org/10.1158/0008-5472.CAN-18-0644CrossRefPubMedPubMedCentral

161.

Papadaki, M. A., Stoupis, G., Theodoropoulos, P. A., Mavroudis, D., Georgoulias, V., & Agelaki, S. (2019). Circulating tumor cells with stemness and epithelial-to-mesenchymal transition features are chemoresistant and predictive of poor outcome in metastatic breast cancer. Molecular Cancer Therapeutics, 18(2), 437–447. https://doi.org/10.1158/1535-7163.MCT-18-0584CrossRefPubMed

162.

Ascierto, P. A., Del Vecchio, M., Mandala, M., Gogas, H., Arance, A. M., Dalle, S., et al. (2020). Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. The lancet Oncology, 21(11), 1465–1477. https://doi.org/10.1016/S1470-2045(20)30494-0CrossRefPubMed

163.

Dummer, R., Brase, J. C., Garrett, J., Campbell, C. D., Gasal, E., Squires, M., et al. (2020). Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF(V600)-mutant, stage III melanoma (COMBI-AD): Exploratory biomarker analyses from a randomised, phase 3 trial. The lancet Oncology, 21(3), 358–372. https://doi.org/10.1016/S1470-2045(20)30062-0CrossRefPubMed

164.

Lampignano, R., Neumann, M., Weber, S., Kloten, V., Herdean, A., Voss, T., Groelz, D., Babayan, A., Tibbesma, M., Schlumpberger, M., Chemi, F., Rothwell, D. G., Wikman, H., Galizzi, J. P., Riise Bergheim, I., Russnes, H., Mussolin, B., Bonin, S., Voigt, C., Musa, H., … Heitzer, E. (2020). Multicenter evaluation of circulating cell-free DNA extraction and downstream analyses for the development of standardized (pre)analytical work flows. Clinical Chemistry, 66(1), 149–160. https://doi.org/10.1373/clinchem.2019.306837

Title: Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors
Authors: Isabel Heidrich
Benjamin Deitert
Stefan Werner
Klaus Pantel
Publication date: 06-01-2023
Publisher: Springer US
Keywords: Prostate Cancer
Metastasis
Melanoma
Melanoma
Breast Cancer
Prostate Cancer
Breast Cancer
Biomarkers
Published in: Cancer and Metastasis Reviews / Issue 1/2023
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-022-10075-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

Could senescence phenotypes strike the balance to promote tumor dormancy?

Newly identified form of phenotypic plasticity of cancer: immunogenic mimicry

Tumor dormancy and disease recurrence

Mesenchymal stromal cell senescence in haematological malignancies

Insights into the role of senescence in tumor dormancy: mechanisms and applications

Biography—Dr. David Gewirtz

Keynote webinar | Spotlight on antibody–drug conjugates in cancer